Stay updated with breaking news from Immune Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
U.S. stocks were higher, with the Dow Jones gaining over 150 points on Thursday.
Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) has been assigned an average recommendation of “Buy” from the seven brokerages that are presently covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have updated their coverage […]
Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) have earned a consensus recommendation of “Buy” from the seven analysts that are currently covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have covered the stock in the […]
-- The Company will present updated data in a late-breaking poster session for povetacicept in IgA nephropathy patients -- -- The Company will host an investor event the same day concurrently with...
Oppenheimer restated their outperform rating on shares of Alpine Immune Sciences (NASDAQ:ALPN – Free Report) in a research report report published on Tuesday morning, Benzinga reports. They currently have a $44.00 price target on the biotechnology company’s stock, up from their previous price target of $33.00. Other research analysts have also issued reports about the […]